Dr. Mina Hosseinipour (left) at one of the UNC-Malawi Project sites in Lilongwe, Malawi. Pictured with her are two of her Clinical Study Coordinators, Cecelia Kanyama
(center) and Nasinuku Saukila (right). | Photo provided by Dannette Smith Cook

Interview: Turning the Tide on an Epidemic

A Native Kentuckian Changes the Deadly Trajectory of HIV Infection | Dannette Smith Cook, M.D.
Tell us a little bit about the work you did that earned Science journal’s Breakthrough of the Year Award in 2011.
I initially went to Lilongwe, Malawi to start the HPTN 052 study
that led to the “breakthrough” of the year. The breakthrough
demonstrated that early antiretroviral therapy can reduce HIV
transmission to a negative partner by 96%. My work on the research protocol largely included developing the research protocol with our chair (Myron S. Cohen) and then building the local
team, training, recruiting discordant couples, and supervising
the implementation of the study. Much of the recruitment included building partnerships with local organizations that perform lots of HIV testing, as well as establishing our own testing
activities. Our site was the leading enrolling site, and we put 251
couples on the study.

D

r. Mina Hosseinipour did not know her
research would positively change the trajectory of the worldwide HIV epidemic when
she graduated with a bachelor’s degree from
the University of Kentucky in the early 1990’s.
In fact, it wasn’t until she was a resident in
internal medicine at Baylor College of Medicine that she decided to pursue a career in
infectious diseases.
This led her to The University of North Carolina (UNC), a world leader in the field of
infectious diseases, where she completed
her fellowship and a concomitant Master’s
of Public Health. During her third and final
year of fellowship, she headed to Africa to
work with the UNC Malawi Project: a cooperative between the Lilongwe Ministry of
Health and UNC to initiate the HIV Prevention Trials Network (HPTN) Study 052.
This landmark study showed that in couples in which one partner is HIV positive
and the other is HIV negative (so-called
“discordant couples”), early anti-retroviral
treatment (ART) in the affected partner causes a marked drop in infection rates of the
non-infected partner. This study was truly a
game-changer, recognized by the prestigious
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How has that seminal paper affected the direction of research in
HIV/AIDS since its publication two years ago?
scientific journal Science as their “Breakthrough of the Year” in 2011. The study was
originally designed to enroll thousands of
discordant couples to treat and track over a
period of 5 years. However, after periodically
reviewing preliminary data, the NIH stopped
the study early. It appeared that the results
were so profound that it was imperative to
offer treatment to all patients meeting the enrollment criteria. These results changed the
trajectory of HIV therapy through the addition of new treatment guidelines to “scale-up
ART.” In fact, the results were so impressive
that they prompted Dr. Hosseinipour’s boss
and the lead author on the study, Dr. Myron
Cohen, to conclude in an interview that “it
makes you actually believe that you can actually see the beginning of an epidemic, and the
end of an epidemic, in one lifetime.”
In addition to this prestigious research, Dr.
Hosseinipour has also co-authored a study
showing reduction in transmission of HIV
from infected mothers to their offspring
when treated with ART while pregnant.
So here we are, with a new paradigm of
“treatment as prevention” and celebrating
one million babies born HIV negative to an

HIV positive mother through the initiatives
of PEPFAR. It is truly a new era for prevention and treatment of HIV around the globe.
Dare we say, “The Downfall of an Epidemic?”
Dr. Hosseinipour and your correspondent
were medicine residents together at Baylor
College of Medicine in Houston. Your correspondent is pleased and proud to share an
interview with Hosseinipour regarding both
her remarkable career and her role in changing the face of the HIV/AIDS epidemic.

On an international scale, the WHO has issued a guideline for
the management of discordant couples largely stating that within all such couples, the HIV infected member should be offered
treatment. More broadly, the HPTN 052 study supported earlier initiation of ART for the general population and the latest
(2013) WHO guidelines support initiation of ART at CD4 of
500 cells (rather than 350). Research now focuses on how earlier treatment (or universal treatment of HIV infected patients)
will reduce HIV transmission on a population level. Countries,
like Malawi, have used the “treatment is prevention” message as
a strong rationale to expand ART treatment to all HIV positive
pregnant women as this provides a maternal health benefit to
the mother, as well as a prevention benefit for the infant and any
HIV negative partner they might have.
Is treatment of infected partners at higher CD4 counts to prevent
transmission to non-infected partners now considered standard
of care?
It is now the WHO recommendation (as well as IAS, DHHS,
etc) but some countries have not yet moved to 500 cells, due to
cost considerations and whether or not the health care infrastructure can accommodate the increased number of patients
that would need care. [WHO- World Health Organization,
IAS- International AIDS Society, DHHS- Department of Health
and Human Services]

Infection rates in Malawi according to UNAIDS stands at 10%.
Remarkably, they describe a 55% drop in the 10 years between
2001 and 2011. How often do you estimate infection rates? Do
you attribute the marked drop in infection rates to more widespread availability of ART?
The Malawi Ministry of Health conducts HIV prevalence estimates alongside UNAIDS annually. This is largely based on a
epidemiology program called “SPECTRUM” that uses inputs
from regularly collected data to estimate the prevalence. In rural South Africa, there was a study that clearly demonstrated
that HIV incidence decreased according to population coverage
of ART (Tanser, et al.). Malawi has even higher coverage than
seen in this article, so I suspect that many of the reductions are
due in part to increased ART coverage. There may be increased
condom use among known positives that could also contribute
to the reduction (among other factors).
In what amount of time would you expect to see a drop in infection rates with new guidelines?
I suspect the trajectory of reduction in new infections will be
somewhat slower than with the initial roll out, as the change is
modest to go from 350 to 500 [CD4 Cell Counts], as compared
to the initial situation where no one was on therapy to the current rates of approximately 60% coverage of those in need at the
350 threshold.
You also co-authored another study showing decrease in vertical
transmission rates in infants whose HIV infected mothers were
given anti-retroviral treatment for at least 12 weeks prior to delivery. Do pregnant women in Malawi frequently make it to delivery without pre-natal care? How can you target (especially HIV
infected) pregnant women for pre-natal care prior to 28 weeks of
pregnancy? Were the CD4 counts in the study participants also
liberalized up to a CD4 count of 500? [PMTCT-Prevention of
Mother to Child Transmission of HIV]
Ninety percent of Malawian women attend at least one antenatal
visit, although most do not present until the mid-to-late second
trimester or even in the third trimester (average 26 weeks). So
for PMTCT, it is important to start early in pregnancy to optimally reduce transmission to the infant. Malawi pioneered an
approach of treating all HIV positive pregnant women regardless of CD4 cell count at the initial visit in which they were identified as positive. (Option B+) This has resulted in over a 700%
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So for PMTCT, it is important to start early in
pregnancy to optimally reduce transmission to
the infant. Malawi pioneered an approach of
treating all HIV positive pregnant women regardless of CD4 cell count at the initial visit in
which they were identified as positive. (Option
B+) This has resulted in over a 700% increase
in the number of HIV infected women starting
ART.

ment hospitals and clinics are free. However,
for medications that are not provided through
the Global Fund, medications are frequently out
of stock, and patients will depart clinics without
these medications. Also, if they are admitted to
the hospital, there are common stock-outs of essential medications and supplies. In these scenarios, patients would go without. [The Global
Fund to Fight AIDS, Tuberculosis, and Malaria]

same phenomenon in Africa. When I arrived
in 2001, death was the reality for HIV patients.
Now, my clinic is a lot of healthy people going
about their usual lives. Imagine if your patient
had survived, if you had reversed his course….
going from a bedridden state, to walking with
a cane, to coming into your office with his new
born baby. It is transformative.

Tell me about the impact on economic and social
development that the HIV/AIDS epidemic has
had in Malawi. UNAIDS discusses the increased
impact on women as well as the devastation in
fields that employ women such as teachers and
healthcare workers (HCW).

You mentioned that you are able to provide ART
through your clinic to patients, but once they are
hospitalized they may not have access to many of
the medications they need. Is that ART as well as
antibiotics, etc? Does the act of being hospitalized become a marker for increasing mortality?
Stated in another way, when an elderly person
falls and breaks a hip, no matter what their health
capacity was prior to the break, their incidence of
all-cause mortality rises significantly during the
year after the break. Do you see a “this is the beginning of the end” scenario when your patients
ultimately do need hospitalization?

What is the typical lifespan of someone who has
received optimal treatment of HIV now? What
are the causes of mortality for patients with HIV
today?

ART would still be available to the patient,
as they can either get an emergency supply
through the hospital clinic, the ART clinic, or
they can take their own. I don’t think the same
holds entirely with our HIV infected patients, as
usually the problem is largely reversible if they
can get through the acute period. But, that gives
me a research idea to evaluate the outcomes of
patients who have had admissions and what follows thereafter.

Grassroots & Citizen
Involvement in HIV.

Certainly, several areas have been affected by
the HIV epidemic including teachers, healthcare workers, military, and police. With respect
to HCW and teachers, the numbers required to
provide services is well below requirements; up
to 70 or 80% of positions in government facilities are unfilled according to the different health
care cadres. And education is the backbone for
the future. Despite the AIDS epidemic, Malawi had enormous population growth (2.8% per
annum), such that the need for these positions
will be even more important. This population
growth is a major barrier to development in
Malawi.
Is your institution able to target rural populations
as well? What are the different barriers to care
between rural and urban affected populations?
Yes, our programs target some rural communities, as we extend our catchment area to 50km
from our facility. This includes rural communities. Distance to health facilities becomes a
larger barrier for rural communities.
What have been some of the roadblocks to healthcare for people infected with HIV/AIDS in Malawi. Are patients able to obtain the medications
they need? Who provides the medications for
those that cannot afford the drugs?
The ART has been free since 2004, so that ART
drug cost is not a barrier. However, the transport costs to get to clinics are difficult for the rural poor. The ART program, (funded through
the Global fund with a parallel procurement
system) has safeguards to prevent stock-outs.
For general health care in Malawi, all govern-

I remember the day I ruled out a career in Infectious Diseases. I have vivid memories of one
particular patient who died from an AIDS-related illness. Unfortunately, sometimes we were
just too late to make a difference, especially in
the early days of ART. I know you must have had
experiences during residency just like that, but
somehow you decided to face it head on. I am curious about that. Was there a particular patient
that affected your decision to go into Infectious
Diseases?
While I won’t target a particular patient, I was
rather struck by how, as an intern in 1995/96,
there was complete hopelessness to HIV, but by
the time I was in my third year as a resident and
ART was now more available, the number of
dying AIDS patients on my service was lower.
By going to the HIV clinic, I could see the hope
and reality of HIV treatment. I see the exact

I haven’t taken care of HIV infected patients in
the US for some time now, but life expectancy
for most HIV infected patients in care (I clarify
“in care”) actually approaches that of HIV uninfected individuals. And the spectrum of illnesses faced by HIV infected patients is similar to
that of any aging population, including cardiovascular disease, liver disease, and renal disease.

I know that UNAIDS has several NGO’s on its program coordination board. Personally, I see the
integration of the field of HIV/AIDS with citizen
diplomacy as being not only an early vanguard
of that type of arrangement, but also a model of
cooperation and mutual respect. Could you touch
on the role that these types of groups have played
in your field? You mentioned that some of these
groups can be helpful because they provide access
to medications outside the “usual channels”. That
certainly reflects influence at a very local level.
What about higher up in the policy making and
funding choices you see in the field?
Certainly community advocacy groups are a
part of the HIV campaign and make their voices heard, particularly at the World AIDS conference. But, more of the meetings and conferences that I attend focus on the science of HIV.
Our research groups have community constituency groups that are part of the scientific process, so that we remain actively engaged in the
needs of community. On a local level in Malawi, our site has a community advisory board
and an active community program in charge of
education. For most policy decisions in which
I’m involved, we really focus on the technical aspect of decision-making, and then the decisions
are presented to the wider range of stakehold-

ers. This ensures that decisions can remain evidence-based, rather than appealing to particular
groups.
Do you see large international agencies as a help
or a hindrance in trying to provide medical care
and social support for Malawians affected with
HIV? In what ways?
I think they are helpful because they increase the
human workforce and often provide supplies in
a way that does not go through the inefficient
(and often corrupt) systems of the Malawi government channels.
Tell me what you like about living in Malawi (or
Africa in general) (Many Patterson students go
on to international careers, often in developing
countries, or in places that no one else has an interest in going!)
Well, as an expatriate, you have a pretty good
quality of life in the sense that you can live securely and can afford to hire staff to help with
the garden, cleaning, cooking, or child care. The
community is also geared to have immediate social circles, usually with other expats also living
abroad. It is sometimes unfortunate how easy it
is to integrate with the other expats, as it limits
your interactions with Malawians. But, I’ve been
in Malawi long enough that I have some Malawi
social circles as well, and you end up feeling like
you live in a small town.
What about living and working in Malawi keeps
you there?
I think the work is the big component. The
range of activities from teaching, research, clinical care, and policy development makes for continued excitement and challenges.
Dr Hosseinipour, thank you so much for sharing
your insights with us. It is truly difficult to fathom the progress that has been made in the last 12
years since you arrived in Malawi. Congratulations and best wishes to you and the UNC-Malawi
Project.
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